Trade Mark Journal No.2021/053 31 December 2021

WO0000001631535 (5)

Office of origin: United States of America

Date of International Registration:10 November 2021
Date of designation in the UK: 10 November 2021
Image for mark 1631535 CETGOFY

International priority date claimed: 4 November 2021 (United States of America) (97109149)
Class 5
Pharmaceutical preparations for the treatment of chronic fibrotic and proliferative disorders; pharmaceutical preparations for the treatment of cancer, muscular dystrophy and idiopathic pulmonary fibrosis.

FibroGen, Inc.

Representative: Harold Milstein Sheppard Mullin Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto CA 94301, UNITED STATES OF AMERICA